Research progress on the treatment of bullous pemphigoid with Dupilumab
In recent years,there have been many reports on the use of Dupilumab in the treat-ment of bullous pemphigoid.Dupilumab specifically binds to the subunit alpha of interleukin 4 re-ceptor(IL-4Rα),blocking the signal transduction of interleukin(IL)-4 and IL-13,inhibiting the proliferation of B cells,reducing the recruitment of eosinophils,and suppressing the function of Th2-related chemotactic factors,thereby improving skin lesions and itching of patients.This arti-cle reviews the potential mechanisms,clinical efficacy,and adverse reactions of Dupilumab in the treatment of bullous pemphigoid.
国家科技期刊平台
NSTL
万方数据
